Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hepatitis C, Chronic | 6 | 2019 | 973 | 1.10 | Why? |
| Carcinoma, Hepatocellular | 3 | 2019 | 1222 | 0.83 | Why? |
| Liver Neoplasms | 3 | 2019 | 1666 | 0.73 | Why? |
| France | 21 | 2021 | 12074 | 0.51 | Why? |
| Liver Cirrhosis | 5 | 2019 | 1810 | 0.50 | Why? |
| Myelodysplastic Syndromes | 3 | 2018 | 261 | 0.44 | Why? |
| Proportional Hazards Models | 4 | 2019 | 6543 | 0.40 | Why? |
| Trisomy | 2 | 2018 | 19 | 0.39 | Why? |
| Erdheim-Chester Disease | 2 | 2018 | 50 | 0.35 | Why? |
| Anus Neoplasms | 2 | 2017 | 123 | 0.31 | Why? |
| Hepatitis B Vaccines | 2 | 2018 | 245 | 0.30 | Why? |
| Myelodysplastic-Myeloproliferative Diseases | 2 | 2018 | 39 | 0.24 | Why? |
| Influenza Vaccines | 2 | 2017 | 2941 | 0.24 | Why? |
| Peripheral Arterial Disease | 2 | 2019 | 471 | 0.24 | Why? |
| Lymphoma | 2 | 2017 | 522 | 0.24 | Why? |
| Antiviral Agents | 8 | 2019 | 41703 | 0.23 | Why? |
| Inflammatory Bowel Diseases | 4 | 2019 | 3209 | 0.21 | Why? |
| Hepatitis B, Chronic | 2 | 2018 | 616 | 0.21 | Why? |
| Hepatitis B virus | 2 | 2017 | 882 | 0.20 | Why? |
| Proto-Oncogene Proteins B-raf | 2 | 2018 | 179 | 0.20 | Why? |
| Cerebral Arterial Diseases | 1 | 2019 | 46 | 0.19 | Why? |
| Simeprevir | 1 | 2019 | 62 | 0.19 | Why? |
| Respiratory Tract Infections | 5 | 2021 | 6817 | 0.19 | Why? |
| Tumor Necrosis Factor-alpha | 2 | 2019 | 2483 | 0.18 | Why? |
| Uridine Monophosphate | 1 | 2017 | 41 | 0.17 | Why? |
| Polychondritis, Relapsing | 1 | 2017 | 20 | 0.17 | Why? |
| Hepatitis B Core Antigens | 1 | 2018 | 76 | 0.17 | Why? |
| Oximes | 1 | 2017 | 51 | 0.17 | Why? |
| Body Composition | 1 | 2021 | 414 | 0.17 | Why? |
| Incidence | 7 | 2021 | 25622 | 0.17 | Why? |
| Respiratory Tract Diseases | 1 | 2005 | 1061 | 0.17 | Why? |
| Sofosbuvir | 2 | 2019 | 518 | 0.17 | Why? |
| Polyethylene Glycols | 3 | 2017 | 574 | 0.16 | Why? |
| Hepatitis B Antibodies | 1 | 2018 | 142 | 0.16 | Why? |
| Behcet Syndrome | 1 | 2018 | 136 | 0.16 | Why? |
| Fluorenes | 1 | 2017 | 101 | 0.16 | Why? |
| Giant Cell Arteritis | 1 | 2019 | 137 | 0.16 | Why? |
| Azathioprine | 1 | 2017 | 161 | 0.16 | Why? |
| DNA, Viral | 2 | 2018 | 2521 | 0.16 | Why? |
| Influenza, Human | 3 | 2017 | 10779 | 0.15 | Why? |
| Cohort Studies | 10 | 2021 | 36005 | 0.15 | Why? |
| Body Weight | 1 | 2021 | 1074 | 0.14 | Why? |
| Interferon-alpha | 2 | 2017 | 1442 | 0.14 | Why? |
| Transitional Care | 1 | 2016 | 135 | 0.14 | Why? |
| Hepatitis B Surface Antigens | 1 | 2017 | 305 | 0.14 | Why? |
| Benzimidazoles | 1 | 2017 | 275 | 0.14 | Why? |
| Cross Infection | 1 | 2017 | 8675 | 0.14 | Why? |
| Communicable Disease Control | 2 | 2021 | 29620 | 0.14 | Why? |
| Middle Aged | 30 | 2021 | 270681 | 0.14 | Why? |
| HIV Protease Inhibitors | 1 | 2017 | 434 | 0.13 | Why? |
| Hepacivirus | 3 | 2019 | 1509 | 0.13 | Why? |
| Rectal Neoplasms | 1 | 2017 | 278 | 0.13 | Why? |
| Oropharynx | 1 | 2021 | 1581 | 0.12 | Why? |
| Adult | 24 | 2021 | 244371 | 0.12 | Why? |
| Aged | 24 | 2021 | 215776 | 0.12 | Why? |
| CD4 Lymphocyte Count | 1 | 2017 | 1517 | 0.12 | Why? |
| Crohn Disease | 2 | 2019 | 959 | 0.12 | Why? |
| Imidazoles | 1 | 2017 | 631 | 0.11 | Why? |
| Opportunistic Infections | 1 | 2018 | 602 | 0.11 | Why? |
| Azetidines | 1 | 2017 | 722 | 0.11 | Why? |
| Orthomyxoviridae | 2 | 2017 | 1168 | 0.11 | Why? |
| Piperidines | 1 | 2017 | 795 | 0.11 | Why? |
| Antiphospholipid Syndrome | 1 | 2017 | 533 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.10 | Why? |
| Immunosuppressive Agents | 2 | 2019 | 6331 | 0.10 | Why? |
| Public Health Surveillance | 2 | 2021 | 3129 | 0.10 | Why? |
| Autoimmunity | 1 | 2017 | 841 | 0.10 | Why? |
| Female | 26 | 2021 | 380317 | 0.10 | Why? |
| Male | 25 | 2021 | 367725 | 0.10 | Why? |
| Humans | 41 | 2021 | 930598 | 0.10 | Why? |
| Chromosomes, Human, Pair 8 | 2 | 2018 | 25 | 0.10 | Why? |
| Phenotype | 2 | 2018 | 4037 | 0.10 | Why? |
| Adolescent | 11 | 2021 | 86841 | 0.10 | Why? |
| Anti-Inflammatory Agents | 2 | 2019 | 6153 | 0.10 | Why? |
| Hepatitis B | 1 | 2017 | 888 | 0.10 | Why? |
| Cerebrovascular Disorders | 1 | 2017 | 1040 | 0.09 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Seroepidemiologic Studies | 2 | 2021 | 10017 | 0.09 | Why? |
| Indoles | 1 | 2017 | 1243 | 0.09 | Why? |
| Sulfonamides | 1 | 2017 | 1294 | 0.09 | Why? |
| Public Policy | 1 | 2021 | 1894 | 0.09 | Why? |
| Heart Diseases | 1 | 2005 | 3503 | 0.09 | Why? |
| Virus Diseases | 1 | 2005 | 3779 | 0.09 | Why? |
| Young Adult | 13 | 2021 | 93724 | 0.09 | Why? |
| Molecular Targeted Therapy | 1 | 2017 | 1579 | 0.09 | Why? |
| Treatment Outcome | 7 | 2019 | 51732 | 0.09 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2017 | 1731 | 0.09 | Why? |
| Hepatitis C | 1 | 2019 | 1514 | 0.09 | Why? |
| Protein Kinase Inhibitors | 1 | 2017 | 1585 | 0.08 | Why? |
| Patient Reported Outcome Measures | 3 | 2017 | 912 | 0.08 | Why? |
| Influenza A Virus, H1N1 Subtype | 2 | 2012 | 2984 | 0.08 | Why? |
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 1439 | 0.08 | Why? |
| Cough | 1 | 2021 | 4891 | 0.08 | Why? |
| Drug Administration Schedule | 3 | 2019 | 2324 | 0.08 | Why? |
| Health Personnel | 1 | 2017 | 29646 | 0.08 | Why? |
| Viruses | 1 | 2020 | 2238 | 0.08 | Why? |
| Child | 6 | 2021 | 70012 | 0.08 | Why? |
| Cholagogues and Choleretics | 1 | 2005 | 11 | 0.08 | Why? |
| Seasons | 2 | 2011 | 4071 | 0.08 | Why? |
| Ursodeoxycholic Acid | 1 | 2005 | 25 | 0.07 | Why? |
| Liver Cirrhosis, Biliary | 1 | 2005 | 42 | 0.07 | Why? |
| Follow-Up Studies | 6 | 2018 | 17020 | 0.07 | Why? |
| Long-Term Care | 1 | 2017 | 2047 | 0.07 | Why? |
| Reagent Kits, Diagnostic | 1 | 2015 | 2149 | 0.07 | Why? |
| Saliva | 1 | 2021 | 4679 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2017 | 2517 | 0.07 | Why? |
| Drug Therapy, Combination | 4 | 2019 | 7268 | 0.07 | Why? |
| Fever | 1 | 2021 | 7795 | 0.07 | Why? |
| Arthritis, Rheumatoid | 1 | 2017 | 2043 | 0.06 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.06 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.06 | Why? |
| Health Status Disparities | 1 | 2021 | 4072 | 0.06 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2017 | 3023 | 0.06 | Why? |
| Nasopharynx | 1 | 2021 | 10224 | 0.06 | Why? |
| Comorbidity | 3 | 2021 | 34796 | 0.06 | Why? |
| Ribavirin | 1 | 2009 | 1182 | 0.06 | Why? |
| Vaccination | 2 | 2017 | 19050 | 0.06 | Why? |
| Prospective Studies | 4 | 2020 | 43301 | 0.05 | Why? |
| Patient Discharge | 1 | 2016 | 5696 | 0.05 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.05 | Why? |
| Mortality | 1 | 2017 | 7132 | 0.05 | Why? |
| Adiposity | 1 | 2021 | 329 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2017 | 8041 | 0.04 | Why? |
| HIV Infections | 2 | 2017 | 11620 | 0.04 | Why? |
| Rhinovirus | 2 | 2015 | 979 | 0.04 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.04 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.04 | Why? |
| Hospitals | 1 | 2016 | 11793 | 0.04 | Why? |
| Hepatitis B e Antigens | 1 | 2017 | 99 | 0.04 | Why? |
| Survival Analysis | 3 | 2018 | 7592 | 0.04 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.04 | Why? |
| Aged, 80 and over | 7 | 2021 | 88759 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Inflammation | 1 | 2018 | 13255 | 0.04 | Why? |
| Antigens, Neoplasm | 1 | 2017 | 230 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.04 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.04 | Why? |
| Parechovirus | 1 | 2015 | 48 | 0.04 | Why? |
| Proline | 1 | 2017 | 345 | 0.04 | Why? |
| Stroke | 1 | 2019 | 8839 | 0.04 | Why? |
| Respirovirus | 1 | 2015 | 122 | 0.04 | Why? |
| Autoantigens | 1 | 2017 | 388 | 0.04 | Why? |
| Risk Assessment | 4 | 2021 | 25439 | 0.04 | Why? |
| Human bocavirus | 1 | 2015 | 142 | 0.04 | Why? |
| Nucleotides | 1 | 2017 | 212 | 0.04 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.03 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.03 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2017 | 262 | 0.03 | Why? |
| Autoimmune Diseases | 2 | 2018 | 1996 | 0.03 | Why? |
| Nucleosides | 1 | 2017 | 221 | 0.03 | Why? |
| Risk Factors | 2 | 2021 | 71621 | 0.03 | Why? |
| Population Surveillance | 1 | 2011 | 4967 | 0.03 | Why? |
| Gram-Positive Bacteria | 1 | 2015 | 230 | 0.03 | Why? |
| Pharmacovigilance | 1 | 2018 | 501 | 0.03 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.03 | Why? |
| Oligopeptides | 1 | 2017 | 576 | 0.03 | Why? |
| Recombinant Proteins | 2 | 2017 | 3786 | 0.03 | Why? |
| Age Factors | 3 | 2019 | 21039 | 0.03 | Why? |
| Antibodies, Antiphospholipid | 1 | 2017 | 519 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Retrospective Studies | 6 | 2019 | 105322 | 0.03 | Why? |
| Enterovirus | 1 | 2015 | 402 | 0.03 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.03 | Why? |
| Respiratory Syncytial Viruses | 1 | 2015 | 612 | 0.03 | Why? |
| Sex Factors | 2 | 2019 | 11014 | 0.03 | Why? |
| Chronic Disease | 1 | 2005 | 5139 | 0.03 | Why? |
| Gram-Negative Bacteria | 1 | 2015 | 473 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2017 | 2437 | 0.03 | Why? |
| Cytomegalovirus | 1 | 2015 | 600 | 0.02 | Why? |
| Case-Control Studies | 2 | 2018 | 17671 | 0.02 | Why? |
| Rituximab | 1 | 2017 | 1096 | 0.02 | Why? |
| Adenoviridae | 1 | 2015 | 1151 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2021 | 51949 | 0.02 | Why? |
| Bayes Theorem | 1 | 2018 | 3237 | 0.02 | Why? |
| Severity of Illness Index | 4 | 2019 | 48226 | 0.02 | Why? |
| Telephone | 1 | 2017 | 1705 | 0.02 | Why? |
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 1458 | 0.02 | Why? |
| Patient Readmission | 1 | 2016 | 1543 | 0.02 | Why? |
| Genotype | 1 | 2019 | 4697 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Coronaviridae | 1 | 2012 | 923 | 0.02 | Why? |
| Infant | 3 | 2015 | 30274 | 0.02 | Why? |
| Biomarkers | 1 | 2009 | 23361 | 0.02 | Why? |
| Child, Preschool | 3 | 2015 | 36283 | 0.02 | Why? |
| Immunity, Herd | 1 | 2012 | 1011 | 0.02 | Why? |
| Disease Progression | 2 | 2018 | 13580 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2017 | 3803 | 0.02 | Why? |
| Symptom Assessment | 1 | 2017 | 4967 | 0.02 | Why? |
| Models, Statistical | 1 | 2021 | 5312 | 0.02 | Why? |
| Socioeconomic Factors | 1 | 2021 | 8495 | 0.02 | Why? |
| Markov Chains | 1 | 2005 | 502 | 0.02 | Why? |
| Primary Health Care | 1 | 2021 | 4839 | 0.02 | Why? |
| Biological Products | 1 | 2017 | 2331 | 0.01 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.01 | Why? |
| Real-Time Polymerase Chain Reaction | 1 | 2021 | 11367 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| Immunologic Factors | 1 | 2017 | 4206 | 0.01 | Why? |
| Obesity | 1 | 2021 | 7388 | 0.01 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.01 | Why? |
| Risk | 1 | 2012 | 5288 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2018 | 8248 | 0.01 | Why? |
| Coinfection | 1 | 2020 | 6820 | 0.01 | Why? |
| Biopsy | 1 | 2009 | 2811 | 0.01 | Why? |
| Internet | 1 | 2017 | 6204 | 0.01 | Why? |
| Mutation | 1 | 2018 | 12376 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2012 | 6740 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 9335 | 0.01 | Why? |
| Pregnancy | 1 | 2017 | 23879 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2011 | 11304 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2019 | 11497 | 0.01 | Why? |
| Liver | 1 | 2009 | 4007 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2005 | 5440 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2021 | 53120 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Emergency Service, Hospital | 1 | 2016 | 14232 | 0.01 | Why? |
| Infant, Newborn | 1 | 2012 | 23105 | 0.01 | Why? |
| Mental Health | 1 | 2017 | 15770 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Time Factors | 1 | 2012 | 31397 | 0.01 | Why? |
| Models, Biological | 1 | 2005 | 4907 | 0.01 | Why? |
| Coronavirus | 1 | 2015 | 18339 | 0.00 | Why? |
| Disease Outbreaks | 1 | 2012 | 27595 | 0.00 | Why? |
Carrat's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(226)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(135)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_